Fig. 3From: Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancerProportion of patients who maintained/improved HRQoL—EORTC QLQ-BR23 in Study 206 (a) and Study 208 (b), ITT populationBack to article page